Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Oral Effects of GLP-1 and GIP Drugs

A 2026 protocol sets out how researchers will map reported oral effects of GLP-1 and dual GLP-1/GIP drugs. It presents no review findings.

Why we wrote this. The paper's title can look like a safety review with settled findings. It is a protocol for a future evidence map, so we separated the planned methods from results that do not yet exist.

In this article (5 sections)
  1. What the protocol is asking
  2. The search is designed to capture mixed evidence
  3. How records and data will be checked
  4. The planned output is an evidence map
  5. What we do not yet know

A BMJ Open paper published on 20 October 2026 is a scoping review protocol, not the completed review. It reports no synthesized findings and no new participant outcomes. The authors have set out how they plan to map reports of oral effects linked with GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists[1]. Symptoms named as targets include dry mouth, altered taste, reduced oral sensation and throat discomfort. Their inclusion in the protocol does not establish that a medicine caused them or show how often they occur.

What the protocol is asking

The research question is broad: what oral adverse effects have been reported with GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists? Eligible medicines include semaglutide, liraglutide, exenatide and dulaglutide, as well as tirzepatide. The team plans to include any population and setting when an oral outcome is reported, whether that outcome was primary or secondary[2].

The planned outcome map reaches beyond symptoms. It includes salivary-flow changes, caries risk, periodontal disease and mucosal changes. The extraction form will also record severity and reversibility when the original report provides them. A single paper may appear in several outcome categories, but the protocol says it will be counted once in the overall study characteristics[2]. That approach describes the range of reports. It does not produce an adverse-event rate by itself.

The search is designed to capture mixed evidence

The authors plan searches in the Cochrane Library, LILACS, MEDLINE/PubMed, Scopus and Web of Science. Google Scholar, ProQuest Dissertations & Theses Global and expert consultation will extend the search, with backward and forward citation tracking through CitationChaser. The protocol places no language or publication-date restriction on eligible records[2].

Eligible designs range from randomized and non-randomized trials to cohort, case-control and cross-sectional research. Case reports, case series and pharmacovigilance database analyses may also enter the map. Animal and in vitro work will be excluded, along with opinion pieces, editorials and narrative reviews[2]. Those sources answer different questions. A spontaneous safety report can flag a possible signal, while a controlled trial is better placed to compare event frequencies under defined conditions.

The protocol also plans to record the treated condition, dose, treatment duration and the method used to measure each oral outcome. Those fields are necessary because a report of dry mouth does not reveal its cause. Diabetes, hydration, diet, other medicines and pre-existing dental disease may influence the same complaint. Even within one outcome label, a patient report, a salivary-flow measurement and a diagnostic code are different observations. The future review can show how often each method appears in the literature, but this protocol contains none of those extracted data[2].

How records and data will be checked

The protocol follows PRISMA-P for protocol reporting and plans to use JBI scoping-review guidance plus PRISMA-ScR for the finished review. It is prospectively registered on the Open Science Framework under DOI 10.17605/OSF.IO/NWTCS. The authors say they will pilot eligibility decisions on 5% of retrieved references before formal screening[2].

Three reviewers are scheduled to assess titles, abstracts and then full texts independently, with a fourth reviewer resolving disagreements when consensus fails. Two reviewers will extract data manually. A third will perform a separate AI-assisted extraction, and the protocol requires every AI-extracted item to be checked manually against the original full text and the independent datasets before inclusion[2]. The proposed checks may reduce selection and transcription errors, but their performance cannot be judged until the completed review reports what happened.

The planned output is an evidence map

The team plans a narrative synthesis with tables, graphs and a geographical map. Descriptive counts, percentages and proportions will summarize the evidence. Exploratory comparisons may separate diabetes from obesity indications and GLP-1 drugs from dual GLP-1/GIP drugs, with attention to dose and treatment duration when reported[2]. The protocol does not propose a pooled treatment-effect estimate. It also does not describe a formal risk-of-bias assessment for the included reports.

That choice fits a scoping review whose job is to show what has been reported and where the gaps sit. It also limits the conclusions. Mixing case reports, surveillance records and trials can reveal the shape of the literature, but it cannot make those designs equally reliable or prove that a drug caused a dental or salivary problem. Descriptive differences between medicines could also reflect who received them, why they were treated and how outcomes were collected.

What we do not yet know

The protocol says its conceptual work began in February 2026, with searching planned for June and completion expected by September 2026[2]. Publication of the protocol after that timetable does not confirm that the review was completed. This paper contains no included-study count, no prevalence estimate and no comparison showing that tirzepatide differs from semaglutide in oral effects.

The useful readout is the prespecified method. A completed review could clarify which oral symptoms have been documented, which evidence comes from pharmacovigilance rather than controlled studies, and which questions lack usable data. Until that synthesis appears, this protocol should not be used to estimate an individual's risk or to change treatment. New or persistent oral symptoms belong in a discussion with the prescribing clinician and a dental professional who can assess other possible causes.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Did this paper find that GLP-1 or GIP drugs cause oral problems?

No. It is a protocol for a future scoping review. It reports no synthesized findings, incidence estimate or new participant outcomes.

Which oral effects will the review look for?

The planned map includes dry mouth, altered taste, reduced oral sensation, throat discomfort, salivary-flow changes, caries risk, periodontal disease and mucosal changes, plus other reported oral outcomes.

Will the completed review prove which medicine caused an oral effect?

Not by itself. The protocol allows evidence ranging from case reports and pharmacovigilance analyses to controlled trials. A scoping review can map those reports, but study design and confounding still determine how strongly causation can be assessed.

Sources

  1. [1]Escudero Samaniego DG et al. Adverse oral effects of GLP-1 and GIP receptor agonists: a scoping review protocol. BMJ Open. 2026. PMID 42901597.Tier 1 · primary↩
  2. [2]Escudero Samaniego DG et al. Full open-access scoping review protocol. BMJ Open. 2026. PMCID PMC13684195.Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars